Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05395481 | A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | PHASE1 | ACTIVE NOT_RECRUITING | 176 | — | — | Jun 8, 2022 | May 1, 2026 | Jan 22, 2026 | 16 | United States, Japan +1 |
A summary of TEAEs and AEs, regardless of causality, will be reported in the Reported Adverse Events module
PD: Mean change from baseline on liver inflammation and fibrosis content measured by MRI
| Arm | Type | Description |
|---|---|---|
| LY3849891 (Part A) | EXPERIMENTAL | Single ascending doses of LY3849891 administered subcutaneously (SC) |
| LY3849891 (Part B) | EXPERIMENTAL | Repeated doses of LY3849891 administered SC |
| Placebo (Part A) | PLACEBO_COMPARATOR | Placebo administered SC |
| Placebo (Part B) | PLACEBO_COMPARATOR | Placebo administered SC |
| Name | Type | Description |
|---|---|---|
| LY3849891 | DRUG | Administered SC |
| Placebo | DRUG | Administered SC |
Inclusion Criteria: * Participants must have a body mass index (BMI) within the range greater than or equal to (≥) 25 and less than (\<) 50 kilogram per square meter (kg/m²) inclusive * Participants must have liver fat content ≥10% in Part A and ≥8% for Part B as determined by MRI-PDFF * Participan...